All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
In March 2018, Xiaojun Huang from Peking University People's Hospital, Beijing, China, and colleagues published the results of a randomized open-label phase III trial (NCT01973387) on ibrutinib versus rituximab for relapsed/refractory (R/R) patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in Cancer Medicine.
Despite the global advances in therapies for CLL/SLL patients, treatment options remain limited in the Asia-Pacific region and especially for difficult-to-treat R/R patients. In China, R/R CLL/SLL patients that do not respond to traditional chemotherapy are limited to rituximab or lenalidomide/thalidomide containing regimens. The aim of this trial was to evaluate the efficacy and safety of ibrutinib versus rituximab for the treatment of R/R CLL/SLL. The primary endpoints of the study were investigator-assessed progression-free survival (PFS), while secondary endpoints included overall response rate (ORR), overall survival (OS), and safety.
The results of this phase III clinical trial indicate the superiority of ibrutinib over rituximab for the treatment of R/R CLL/SLL patients in the Asia-Pacific region. With similarly acceptable safety profiles, ibrutinib improved PFS, ORR and OS, when compared to rituximab treatment. According to the authors, these results are consistent with other global studies, indicating that ibrutinib’s efficacy and safety over rituximab is comparable to the values observed for the general population.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox